IBI322, an anti-CD47/PD-L1 bispecific monoclonal antibody, was designed with a monovalent CD47-binding domain and bivalent PD-L1-binding domain, to enable selective tumor targeting and spare red blood cells [107,108]. Here, CD274 is linked to neoplasm.